BMO Capital Markets Reaffirms Outperform Rating for Regeneron Pharmaceuticals (NASDAQ:REGN)

BMO Capital Markets restated their outperform rating on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a research note published on Tuesday morning, Benzinga reports. The firm currently has a $1,300.00 price objective on the biopharmaceutical company’s stock.

REGN has been the subject of a number of other research reports. Canaccord Genuity Group reiterated a buy rating and set a $1,152.00 target price on shares of Regeneron Pharmaceuticals in a report on Thursday, June 27th. Royal Bank of Canada reiterated an outperform rating and set a $1,282.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 17th. Argus raised their target price on shares of Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the company a buy rating in a research note on Tuesday, June 25th. Leerink Partners restated a market perform rating and set a $1,077.00 target price (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday. Finally, Morgan Stanley lowered their price target on Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an overweight rating for the company in a report on Thursday, July 11th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of Moderate Buy and an average target price of $1,118.62.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $1,039.96 on Tuesday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.62 and a current ratio of 5.44. The firm has a market capitalization of $114.59 billion, a price-to-earnings ratio of 30.72, a price-to-earnings-growth ratio of 3.72 and a beta of 0.12. Regeneron Pharmaceuticals has a one year low of $769.19 and a one year high of $1,211.20. The company has a 50 day moving average price of $1,129.87 and a 200 day moving average price of $1,033.99.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The business had revenue of $3.55 billion during the quarter, compared to the consensus estimate of $3.38 billion. During the same period in the prior year, the firm posted $8.79 EPS. The business’s revenue for the quarter was up 12.3% on a year-over-year basis. Sell-side analysts anticipate that Regeneron Pharmaceuticals will post 37.8 EPS for the current year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $1,059.24, for a total value of $105,924.00. Following the completion of the sale, the director now directly owns 17,882 shares in the company, valued at approximately $18,941,329.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $1,059.24, for a total value of $105,924.00. Following the completion of the transaction, the director now directly owns 17,882 shares of the company’s stock, valued at approximately $18,941,329.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Marion Mccourt sold 1,137 shares of the stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $1,047.11, for a total transaction of $1,190,564.07. Following the sale, the executive vice president now owns 12,931 shares in the company, valued at approximately $13,540,179.41. The disclosure for this sale can be found here. Insiders have sold 9,270 shares of company stock worth $10,695,833 over the last quarter. 7.48% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the stock. West Paces Advisors Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 575.0% during the first quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 23 shares during the period. Stephens Consulting LLC bought a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at about $26,000. Sachetta LLC boosted its stake in Regeneron Pharmaceuticals by 71.4% during the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 10 shares during the period. Crewe Advisors LLC bought a new position in Regeneron Pharmaceuticals in the 1st quarter worth about $28,000. Finally, Lynx Investment Advisory acquired a new stake in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $33,000. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.